Phibro Animal Health Corp - Company Profile
Powered by 
All the sales intelligence you need on Phibro Animal Health Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Phibro Animal Health Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Phibro Animal Health Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Phibro Animal Health Corp (Phibro), a subsidiary of BFI Co LLC, is an animal health and mineral nutrition company. The company focuses on developing, manufacturing, and marketing products that enhance the health and well-being of food and companion animals. Its major products include antibacterials, anticoccidials, nutritional speciality products, vaccines, and mineral nutrition products. It caters its products to livestock producers, farmers, and veterinarians. The company sells its products directly to integrated poultry, swine and cattle integrators and through commercial animal feed manufacturers, wholesalers and distributors. It operates in markets across North America, Latin America, Asia Pacific, Europe, Africa, and the Middle East. Phibro is headquartered in Teaneck, New Jersey, the US.
Headquarters
United States of America
Address
Suite 21,Glenpointe Centre East, 3rd Floor, 300 Frank W. Burr Boulevard, Teaneck, New Jersey, 07666
Website
www.pahc.com
Telephone
1 201 3297300
No of Employees
2,475
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PAHC (NASD)
Revenue (2024)
$1.3B
27.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
1897.7%
(2024 vs 2023)
Market Cap*
$1.3B
Net Profit Margin (2024)
XYZ
1,450.0%
(2024 vs 2023)
* As of and is in US$
Phibro Animal Health Corp premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Animal Health and Nutrition: | Feeding Management Support: | AB20 |
| Anthelmintics | Time-Lapse Video Recording and Evaluation | Aureomycin |
| Antibiotics | Total Mixed Ration (TMR) Analysis | KinetX |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company entered into an agreement with Lighthouse Pharmaceuticals, Inc. to develop a novel therapeutic asset targeting periodontal health in companion animals. |
| 2025 | New Products/Services | In October, the company introduced Restoris piezoelectric dental gel for dogs. |
| 2024 | Acquisitions/Mergers/Takeovers | In October, the company acquired Zoetis’ medicated feed additive product portfolio and certain water-soluble products. |
Competitor Comparison
| Key Parameters | Phibro Animal Health Corp | Archer Daniels Midland Co | Boehringer Ingelheim International GmbH | Zoetis Inc | Elanco Animal Health Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Germany | United States of America | United States of America |
| City | Teaneck | Chicago | Ingelheim am Rhein | Parsippany | Indianapolis |
| State/Province | New Jersey | Illinois | Rheinland-Pfalz | New Jersey | Indiana |
| No. of Employees | 2,475 | 40,798 | 54,300 | 14,500 | 9,400 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jack C. Bendheim | Chairman | Executive Board | 2014 | 79 |
| Daniel M. Bendheim | President; Chief Executive Officer | Senior Management | 2026 | 54 |
| Glenn C. David | Chief Financial Officer | Senior Management | 2024 | 55 |
| Larry L. Miller | Chief Operating Officer | Senior Management | 2016 | 62 |
| Joyce J. Lee | Director - Director | Non Executive Board | 2025 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer